EPO-TRAUMA Trial

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multi-centre, stratified, double-blind, randomised, placebo-controlled trial. (The EPO-TRAUMA trial)

ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients

Sites32
Patients846

Committee
Contacts
Progress

Study Progress

Country	Recruited
Australia	468
New Zealand	165
Finland	70
Switzerland	59
Saudi Arabia	43
Ireland	31
Slovenia	10
Total	846